个体化治疗软件对乳腺癌术后辅助化疗有效性的验证研究(1)
 |
| 第1页 |
参见附件(3034KB，3页)。
[摘要] 目的：通过回顾性的生存期分析研究，来验证黄新恩博士开发的乳腺癌个体化治疗软件的临床实用价值。方法：研究对象为在江苏省肿瘤医院行乳腺癌切除术，术后病理确诊为乳腺癌并接受术后辅助化疗的患者。入组患者被分为三组，A组实际治疗方案与软件预测完全相同，B组实际治疗方案与软件预测部分相同，C组实际治疗方案与软件预测完全不同。通过比较A、B、C组生存期来验证乳腺癌个体化治疗软件的有效性。结果：从1992年12月～2007年7月，310例女性乳腺癌患者随机入组本项研究。A、B、C组患者数目分别为102、115、93例。通过绘制生存曲线，进行生存分析，结果发现A组与B组(P=0.000 4)、A组与C组(P=0.004 6)生存期差异均有统计学意义。A组患者预后分别优于B组和C组。结论：本验证研究证实乳腺癌个体化治疗软件能够对乳腺癌患者术后辅助化疗提供很有价值的临床指导，具有良好的实际应用价值，值得推广应用。
[关键词] 乳腺癌；医学软件；术后化疗；生存期
[中图分类号] R737.9 [文献标识码]A [文章编号]1673-7210(2011)04(a)-024-03
A validation study on efficacy of individualized treatment software for breast cancer patients who received postoperative adjuvant chemotherapy
JIANG Yong1, HUANG Xin′en1, YAN Pengwei1, XU Jianwei2, XIANG Jin3, CUI Lin4
1.Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University, Nanjing 210009, China; 2.Department of Oncology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing 210028, China; 3.Department of Scientific Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University, Nanjing 210009, China; 4.Department of Oncology, the People′s Hospital of Jiangyan City, Jiangyan 225500, China
[Abstract] Objective: To validate the clinical value of an individualized treatment software which developed by Doctor HUANG Xin′en. Methods: Patients with histologically confirmed breast cancer after mastectomy who received postoperative chemotherapy in Jiangsu Cancer Hospital were recruited in this study. All eligible patients were divided into group A,B, C. Group A, regimen of practical chemotherapy was consistent with software predication; group B, partly consistent with software predication; group C, inconsistent with software predication. Overall survival (OS) were compared among group A, B and C to determine the efficacy of individualized treatment software. Results: From December 1992 to July 2007, 310 female breast cancer patients were recruited into this study ......
您现在查看是摘要介绍页，详见PDF附件(3034KB，3页)。